{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T04:19:29Z","timestamp":1776313169057,"version":"3.50.1"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy & Behavior"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.yebeh.2021.108371","type":"journal-article","created":{"date-parts":[[2021,10,28]],"date-time":"2021-10-28T09:04:45Z","timestamp":1635411885000},"page":"108371","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Tolerability of antiseizure medicines using Lithuanian version of the Liverpool Adverse Events Profile"],"prefix":"10.1016","volume":"124","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5656-4663","authenticated-orcid":false,"given":"Arminas","family":"Jasionis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabija","family":"Jasionyt\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u016bta","family":"Mameni\u0161kien\u0117","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"15","key":"10.1016\/j.yebeh.2021.108371_b0005","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1212\/01.wnl.0000259411.78423.50","article-title":"Quality of life outcomes of immediate or delayed treatment of early epilepsy and single seizures","volume":"68","author":"Jacoby","year":"2007","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108371_b0010","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1001\/jamaneurol.2017.3949","article-title":"Treatment outcomes in patients with newly diagnosed epilepsy treated with established and new antiepileptic drugs: A 30-year longitudinal cohort study","volume":"75","author":"Chen","year":"2018","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.yebeh.2021.108371_b0015","doi-asserted-by":"crossref","unstructured":"Cramer JA, Steinborn B, Striano P, et al. Non-interventional surveillance study of adverse events in patients with epilepsy. Acta Neurol Scand. 2011;124(1):13\u201321.","DOI":"10.1111\/j.1600-0404.2010.01440.x"},{"issue":"1","key":"10.1016\/j.yebeh.2021.108371_b0020","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.yebeh.2008.02.006","article-title":"Strategies to detect adverse effects of antiepileptic drugs in clinical practice","volume":"13","author":"Carre\u00f1o","year":"2008","journal-title":"Epilepsy Behav"},{"issue":"14","key":"10.1016\/j.yebeh.2021.108371_b0025","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1212\/01.wnl.0000345667.45642.61","article-title":"Adverse antiepileptic drug effects: toward a clinically and neurobiologically relevant taxonomy","volume":"72","author":"Perucca","year":"2009","journal-title":"Neurology"},{"issue":"10 Suppl 4","key":"10.1016\/j.yebeh.2021.108371_b0030","first-page":"S9","article-title":"Tolerability of antiseizure medications: implications for health outcomes","volume":"63","author":"Gilliam","year":"2004","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108371_b0035","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1056\/NEJM200002033420503","article-title":"Early identification of refractory epilepsy","volume":"342","author":"Kwan","year":"2000","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.yebeh.2021.108371_b0040","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108371_b0045","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1212\/WNL.0b013e318207b073","article-title":"Adverse antiepileptic drug effects in new-onset seizures: a case-control study","volume":"76","author":"Perucca","year":"2011","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108371_b0050","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.yebeh.2011.08.005","article-title":"Are adverse effects of antiepileptic drugs different in symptomatic partial and idiopathic generalized epilepsies? The Portuguese-Brazilian validation of the Liverpool Adverse Events Profile","volume":"22","author":"Martins","year":"2011","journal-title":"Epilepsy Behav"},{"issue":"8","key":"10.1016\/j.yebeh.2021.108371_b0055","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.seizure.2012.06.003","article-title":"Severity of anxiety and depression are related to a higher perception of adverse effects of antiepileptic drugs","volume":"21","author":"G\u00f3mez-Arias","year":"2012","journal-title":"Seizure"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108371_b0060","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yebeh.2008.11.016","article-title":"Validation of the Spanish version of the Liverpool Adverse Events Profile in patients with epilepsy","volume":"15","author":"Carre\u00f1o","year":"2009","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108371_b0065","doi-asserted-by":"crossref","first-page":"8490639","DOI":"10.1155\/2018\/8490639","article-title":"Adverse events of antiepileptic drugs using Indonesian Version of Liverpool Adverse Events Profile","volume":"2018","author":"Budikayanti","year":"2018","journal-title":"Neurol Res Int"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108371_b0070","doi-asserted-by":"crossref","first-page":"317","DOI":"10.4103\/ijmr.IJMR_710_15","article-title":"Adverse effects & drug load of antiepileptic drugs in patients with epilepsy: Monotherapy versus polytherapy","volume":"145","author":"Joshi","year":"2017","journal-title":"Indian J Med Res"},{"key":"10.1016\/j.yebeh.2021.108371_b0075","doi-asserted-by":"crossref","unstructured":"Canevini MP, De Sarro G, Galimberti CA, et al. Relationship between adverse effects of antiepileptic drugs, number of coprescribed drugs, and drug load in a large cohort of consecutive patients with drug-refractory epilepsy. Epilepsia. 2010;51(5):797\u2013804.","DOI":"10.1111\/j.1528-1167.2010.02520.x"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108371_b0080","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1111\/j.1528-1167.2006.00956.x","article-title":"The Liverpool Adverse Events Profile: relation to AED use and mood","volume":"48","author":"Panelli","year":"2007","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108371_b0085","doi-asserted-by":"crossref","first-page":"107309","DOI":"10.1016\/j.yebeh.2020.107309","article-title":"Validation of the Serbian version of the Liverpool Adverse Events Profile of antiseizure therapy in patients with epilepsy","volume":"111","author":"Soki\u0107","year":"2020","journal-title":"Epilepsy Behav"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108371_b0090","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1528-1167.2012.03500.x","article-title":"Epilepsy and psychiatric comorbidity: a nationally representative population-based study","volume":"53","author":"Rai","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108371_b0095","first-page":"59","article-title":"The Liverpool Adverse Events Drug Profile","volume":"36","author":"Baker","year":"1995","journal-title":"Epilepsia"},{"issue":"1-2","key":"10.1016\/j.yebeh.2021.108371_b0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.eplepsyres.2011.01.008","article-title":"Validation of the Chinese version of the Liverpool Adverse Events Profile in patients with epilepsy","volume":"94","author":"Chen","year":"2011","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2021.108371_b0105","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.yebeh.2014.08.124","article-title":"Translation, cross-cultural adaptation, and validation of the Bulgarian version of the Liverpool Adverse Event Profile","volume":"39","author":"Kuzmanova","year":"2014","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2021.108371_b0110","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.yebeh.2018.01.028","article-title":"Liverpool Adverse Events Profile: Italian validation and predictive value for dropout from antiepileptic treatment in people with epilepsy","volume":"81","author":"Romoli","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108371_b0115","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: a practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108371_b0120","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1111\/j.1528-1157.1997.tb01142.x","article-title":"Reappraisal of polytherapy in epilepsy: A critical review of drug load and adverse effects","volume":"38","author":"Deckers","year":"1997","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108371_b0125","unstructured":"World Health Organization Collaborating Centre for Drug Statistics Methodology. Guidelines for ATC classification and DDD assignment. 2020."},{"issue":"10","key":"10.1016\/j.yebeh.2021.108371_b0130","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.yebeh.2021.108371_b0135","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.yebeh.2018.12.006","article-title":"Optimal cutoff score of the Neurological Disorders Depression Inventory for Epilepsy (NDDI-E) for detecting major depressive disorder: A meta-analysis","volume":"92","author":"Kim","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"5","key":"10.1016\/j.yebeh.2021.108371_b0140","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1016\/S1474-4422(06)70415-X","article-title":"Rapid detection of major depression in epilepsy: a multicentre study","volume":"5","author":"Gilliam","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2021.108371_b0145","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.yebeh.2014.04.005","article-title":"Validation of the Generalized Anxiety Disorder-7 in people with epilepsy: A MEPSY study","volume":"35","author":"Seo","year":"2014","journal-title":"Epilepsy Behav"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108371_b0150","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1111\/epi.13709","article-title":"ILAE classification of the epilepsies: Position paper of the ILAE Commission for Classification and Terminology","volume":"58","author":"Scheffer","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108371_b0155","first-page":"80","article-title":"Initial development, reliability, and validity of a patient-based adverse event scale","volume":"35","author":"Baker","year":"1994","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.yebeh.2021.108371_b0160","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1111\/j.1528-1167.2012.03488.x","article-title":"Depressive and anxiety disorders in epilepsy: do they differ in their potential to worsen common antiepileptic drug-related adverse events?","volume":"53","author":"Kanner","year":"2012","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108371_b0165","first-page":"508","article-title":"Update on antiepileptic drugs 2019","volume":"25","author":"Abou-Khalil","year":"2019","journal-title":"Contin Minneap Minn"},{"issue":"4","key":"10.1016\/j.yebeh.2021.108371_b0170","doi-asserted-by":"crossref","first-page":"e70","DOI":"10.1111\/epi.13707","article-title":"Comparison of levetiracetam and oxcarbazepine monotherapy among Korean patients with newly diagnosed focal epilepsy: A long-term, randomized, open-label trial","volume":"58","author":"Kim","year":"2017","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2021.108371_b0175","doi-asserted-by":"crossref","first-page":"106408","DOI":"10.1016\/j.eplepsyres.2020.106408","article-title":"Comparison of long-term efficacy, tolerability, and safety of oxcarbazepine, lamotrigine, and levetiracetam in patients with newly diagnosed focal epilepsy: An observational study in the real world","volume":"166","author":"Li","year":"2020","journal-title":"Epilepsy Res"},{"issue":"3","key":"10.1016\/j.yebeh.2021.108371_b0180","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.seizure.2007.09.001","article-title":"Stigma, seizure frequency and quality of life: the impact of epilepsy in late adulthood","volume":"17","author":"McLaughlin","year":"2008","journal-title":"Seizure"},{"issue":"9","key":"10.1016\/j.yebeh.2021.108371_b0185","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1037\/0003-066X.47.9.1134","article-title":"Psychopathology in epilepsy: The role of psychology in altering paradigms of research, treatment, and prevention","volume":"47","author":"Hermann","year":"1992","journal-title":"Am Psychol"},{"issue":"2","key":"10.1016\/j.yebeh.2021.108371_b0190","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1037\/0033-295X.96.2.234","article-title":"Health complaints, stress, and distress: exploring the central role of negative affectivity","volume":"96","author":"Watson","year":"1989","journal-title":"Psychol Rev"}],"container-title":["Epilepsy & Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021006326?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505021006326?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:40:17Z","timestamp":1761504017000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505021006326"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":38,"alternative-id":["S1525505021006326"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108371","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tolerability of antiseizure medicines using Lithuanian version of the Liverpool Adverse Events Profile","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2021.108371","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108371"}}